Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

Nucleic Acids Research

Volumn 34, Issue 6, 2006, Pages

  Liedert, Bernd ^a   Pluim, Dick ^b   Schellens, Jan ^b   Thomale, Jürgen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CISPLATIN; DNA; GUANINE; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCISION REPAIR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOASSAY; KIDNEY TUBULE CELL; KINETICS; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH CANCER; T LYMPHOCYTE; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CHEMISTRY; DNA REPAIR; EVALUATION; FLUORESCENT ANTIBODY TECHNIQUE; HYBRIDOMA; IMMUNOLOGY; LEUKEMIA CELL LINE; MALE; METHODOLOGY; PATHOLOGY; STOMACH TUMOR;

ANIMALIA;

ADENINE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GUANINE; HUMANS; HYBRIDOMAS; IMMUNOASSAY; JURKAT CELLS; MALE; MICE; MICE, INBRED C57BL; STOMACH NEOPLASMS;

EID: 33645511438     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl051     Document Type: Article

References (52)

1. Rosenberg,B., van Camp,L. and Krigas,T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205, 698-699.
2. O'Dwyer,P.J., Stevenson,J.P. and Johnson,S.W. (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs, 59, 19-27.
3. Decatris,M.P., Sundar,S. and O'Byrne,K.J. (2004) Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat. Rev., 30, 53-81.
4. Siddik,Z.H. (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-7279.
5. Timmer-Bosscha,H., Mulder,N.H. and de Vries,E.G. (1992) Modulation of cis-diamminedichloroplatinum(II) resistance: A review. Br. J. Cancer., 60, 227-238.
6. Cornelison,T.L. and Reed,E. (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol. Oncol., 50, 147-158.
7. Cano,J.R., Catalan,B. and Jara,C. (1998) Neuronopathy due to cisplatin. Rev. Neurol., 27, 606-610.
8. Smoorenburg,G.F., De-Groot,J.C., Hamers,F.P. and Klis,S.F. (1999) Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann. NY Acad. Sci., 884, 192-210.
9. Kartalou M., Essigmann J.M. (2001), Mechanisms of resistance to cisplatin. Mutat. Res., 478, 23-43.
10. Blommaert,F.A., van Dijk-Knijnenburg,H.C.M., Dijt,F.J., den Engelse,L., Baan,R.A., Berends,F. and Fichtinger-Schepman,A.M.J. (1995) Formation of DNA adducts by the anticancer drug carboplatin. Different nucleotide sequence preferences in vitro and in cells. Biochemistry, 34, 8474-8480.
11. Johnsson,A., Olsson,C., Nygren,O., Nilsson,M., Seiving,B. and Cavallin-Stahl,E. (1995) Pharmacokinetics and tissue distribution of cisplatin in nude mice: Platinum levels and cisplatin-DNA adducts. Cancer Chemother. Pharmacol., 37, 23-31.
12. Terheggen,P.M.A.B., Floot,B.G., Scherer,E., Begg,A.C., Fichtinger-Schepman,A.M.J. and den Engelse,L. (1987) Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissue sections. Cancer Res., 47, 6719-6725.
13. Schellens,J.H.M., Ma,J., Planting,A.S., Th., van der Burg,M.E.L., van Meerten,E., de Boer-Dennert,M., Schmitz,P.I.M., Stoter,G. and Verweij,J. (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer, 73, 1569-1575.
14. Liedert,B., Materna,V., Schadendorf,D., Thomale,J. and Lage,H. (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DANN adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J. Invest. Dermatol., 121, 172-176.
15. Meijer,C., Timmer,A., de-Vries,E.G., Groten,J.P., Knol,A., Zwart,N., Dam,W.A.,Sleijfer,D.T. and Mulder,N.H. (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int. J. Cancer, 85, 777-781.
16. Crul,M., Schellens,J.H.M., Beijnen,J.H. and Maliepaard,M. (1997) Cisplatin resistance and DNA repair. Cancer Treat. Rev., 23, 341-366.
17. Chen,Z., Xu,X.S., Yang,J. and Wang,G. (2003) Defining the function of XPC protein in psoralen and cisplatin-mediated DANN repair and mutagenesis. Carcinogenesis, 24, 1111-1121.
18. Furuta,T., Ueda,T., Aune,G., Sarasin,A., Kraemer,K.H. and Pommier,Y. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res., 62, 4899-4902.
19. McHugh,P.J., Spanswick,V.J. and Hartley,J.A. (2001) Repair of DNA interstrand crosslinks: Molecular mechanisms and clinical relevance. Lancet Oncol., 2, 483-490.
20. Fichtinger-Schepman,A.M.J., Lohman,P.H.M. and Reedijk,J. (1982) Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res., 10, 5345-5356.
21. Reed,E., Parker,R.J., Gill,I., Bicher,A., Dabholkar,M., Vionnet,J.A., Bostick-Bruton,F., Tarone,R. and Muggia,F.M. (1993) Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res., 53, 3694-3699.
22. Bonetti,A., Apostoli,P., Zaninelli,M., Pavanel,F., Colombatti,M., Cetto,G.L., Franceschi,T., Sperotto,L. and Leone,R. (1996) Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin. Cancer Res., 2, 1829-1835.
23. 32P-postlabelling. Nucleic Acids Res., 23, 126-132.
24. 32P DNA radiolabeling and two-dimensional thin-layer chromatography: A time and concentration study. Cancer Invest., 18, 314-326.
25. 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. Anal. Biochem., 275, 30-38.
26. Fichtinger-Schepman,A.M.J., van Oosterom,A.T., Lohman,P.H.M. and Berends,F. (1987) Cis-diammine-dichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction und removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res., 47, 3000-3004.
27. Meijer,C., de Vries,E.G.E., Dam,W.A., Wilkinson,M.H.F., Hollema,H., Hoekstra,H.J. and Mulder,N.H. (1997) Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy. Br. J. Cancer, 76, 290-298.
28. Poirier,M.C., Lippard,S.J., Zwelling,L.A., Ushay,H.M., Kerrigan,D., Thill,C.C., Santella,R.M., Grunberger,D. and Yuspa,S.H. (1982) Antibodies elicited against cis-diamminedichloroplatinum (II)-modified DNA are specific for cis-diamminedichloroplatinum (II) - DNA adducts formed in vivo and in vitro. Proc. Natl. Acad. Sci. USA, 79, 6443-6447.
29. Terheggen,P.M., Floot,B.G., Lempers,E.L., van Tellingen,O., Begg,A.C. and den Engelse,L. (1991) Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother. Pharmacol., 28, 185-191.
30. Tilby,M.J., Johnson,C., Knox,R.J., Cordell,J., Roberts,J.J. and Dean,C.J. (1991) Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res., 51, 123-129.
31. Chao,C.C., Shieh,T.-C. and Huang,H. (1994) Use of a monoclonal antibody to detect DNA damage caused by the anticancer drug cis-diamminedichloroplatinum (II) in vivo and in vitro. FEBS Lett., 354, 103-109.
32. Sundquist,W.I., Lippard,S.J. and Stollar,B.D. (1987) Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum (II). Proc. Natl Acad. Sci. USA, 84, 8225-8229.
33. Meczes,E.L., Azim-Araghi,A., Ottley,C.J., Pearson,D.G. and Tilby,M.J. (2005) Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA. Biochem. Pharmacol., 70, 1717-1725.
34. Reed,E., Sauerhoff,S. and Poirier,M.C. (1988) Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: A novel use of graphite furnace spectrometry. Atomic Spectroscopy, 9, 93-95.
35. Eberle,G., Gluesenkamp,K.H., Drosdziok,W. and Rajewsky,M.F. (1990) Monoclonal antibodies for the specific detection of 3-alkyladenines in nucleic acids and body fluids. Carcinogenesis, 11, 1753-1759.
36. Barcellini,W., Borghi,M.O., Fain,C., Papa,N., Nicoletti,F. and Meroni,P.L. (1992) Enrichment of IgG Anti-DNA producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. Clin. Immunol. Immunopathol., 65, 39-44.
37. Ossendorp,F.A., Bruning,P.F., Van den Brink,J.A.M. and De Boer,M. (1989) Efficient selection of high-affinity B cell hybridomas using antigen-coated magnetic beads. J. Immunol. Methods, 120, 191-200.
38. Coller,H.A. and Coller,B.S. (1983) Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. Hybridoma, 2, 91-96.
39. Coulter,A.R., Cox,J.C., Harris,R.D. and Healey,K. (1989) An enzyme immunoassay for isotyping mouse monoclonal antibodies. Med. Lab. Sci., 46, 54-58.
40. Hutchens,T.W. and Porath,J. (1986) Thiophilic adsorption of immunoglobulins - analysis of conditions optimal for selective immobilization and purification. Anal. Biochem., 159, 217-226.
41. Fleming,J.O. and Pen,L.B. (1988) Measurement of the concentration of murine IgG monoclonal antibody in hybridoma supernatants and ascites in absolute units by sensitive and reliable enzyme-linked immunosorbent assays (ELISA). J. Immunol. Methods, 110, 11-18.
42. Seiler,F., Kirstein,U., Eberle,G., Hochleitner,K. and Rajewsky,M.F. (1993) Quantification of specific DNA O-alkylation products in individual cells by monoclonal antibodies and digital imaging of intensified nuclear fluorescence. Carcinogenesis, 14, 1907-1913.
43. Horton,J.K., Evans,O.M., Swann,K. and Swinburne,S. (1989) A new and rapid method for the selection and cloning of antigen-specific hybridomas with magnetic microspheres. J. Immunol. Methods, 124, 225-230.
44. Egeland,T., Hovdenes,A. and Lea,T. (1988) Positive selection of antigen-specific B lymphocytes by means of immunomagnetic particles. Scand. J. Immunol., 27, 439-444.
45. Hebell,T. and Gotze,O. (1989) The isolation of B lymphocytes from human peripheral blood using antibodies coupled to paramagnetic particles and rosetting techniques. J. Immunol. Methods, 123, 283-291.
46. Hochleitner,K., Thomale,J., Nikitin,A. and Rajewsky,M.F. (1991) Monoclonal antibody-based, selective isolation of DNA fragments containing an alkylated base to be quantified in defined gene sequences. Nucleic Acids Res., 19, 4467-4472.
47. Lau,A.H. (1999) Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int., 56, 1295-1298.
48. Kelland,L.R. (1994) The molecular basis of cisplatin sensitivity/ resistance. Eur. J. Cancer, 30, 725-727.
49. Fichtinger-Schepman,A.M., van der Velde-Visser,S.D., van Dijk-Knijnenburg,H.C., van Oosterom,A.T., Baan,R.A. and Berends,F. (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res., 50, 7887-7894.
50. Mustonen,R., Takala,M., Leppala,S. and Hemminki,K. (1989) Dose-dependence and stability of cisplatin binding to tissue DNA and blood proteins in rats. Carcinogenesis, 10, 365-368.
51. Knox,R.J., Friedlos,F., Lydall,D.A. and Roberts,J.J. (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutane-dicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972-1979.
52. Poirier,M.C., Reed,E., Shamkhani,H., Tarone,R.E. and Gupta-Burt,S. (1993) Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ. Health Perspect., 99, 149-154.